Femasys Inc. (NASDAQ:FEMY) Short Interest Update

Femasys Inc. (NASDAQ:FEMY) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 776,900 shares, a drop of 6.9% from the May 31st total of 834,700 shares. Based on an average daily trading volume, of 277,000 shares, the short-interest ratio is currently 2.8 days. Approximately 3.8% of the shares of the company are sold short.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Femasys stock. Clear Creek Financial Management LLC lifted its position in shares of Femasys Inc. (NASDAQ:FEMY) by 30.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 309,274 shares of the company’s stock after buying an additional 72,505 shares during the quarter. Clear Creek Financial Management LLC owned approximately 1.40% of Femasys worth $479,000 at the end of the most recent quarter. Institutional investors own 65.27% of the company’s stock.

Femasys Price Performance

Shares of NASDAQ FEMY traded down $0.06 during trading on Tuesday, hitting $1.11. 82,783 shares of the company were exchanged, compared to its average volume of 465,503. The company has a market cap of $24.66 million, a price-to-earnings ratio of -1.32 and a beta of -2.81. Femasys has a 1 year low of $0.25 and a 1 year high of $4.75. The firm’s fifty day moving average price is $1.20 and its 200 day moving average price is $1.26. The company has a debt-to-equity ratio of 0.29, a current ratio of 8.43 and a quick ratio of 8.02.

Femasys (NASDAQ:FEMY) last issued its earnings results on Thursday, May 9th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.05. The company had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.30 million. Femasys had a negative net margin of 1,420.59% and a negative return on equity of 104.06%. On average, sell-side analysts expect that Femasys will post -0.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on FEMY. Jonestrading lifted their price objective on shares of Femasys from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th. Chardan Capital restated a “buy” rating and set a $12.00 target price on shares of Femasys in a research report on Monday, April 1st. Finally, HC Wainwright restated a “buy” rating and set a $13.00 target price on shares of Femasys in a research report on Thursday, June 20th.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.